Literature DB >> 33478423

A nomogram based on pretreatment levels of serum bilirubin and total bile acid levels predicts survival in colorectal cancer patients.

Yinghao Cao1, Shenghe Deng1, Lizhao Yan1, Junnan Gu1, Jia Yang2, Ming Yang3, Li Liu4, Kailin Cai5.   

Abstract

BACKGROUND: Serum bilirubin and total bile acid (TBA) levels have been reported to be strongly associated with the risk and prognosis of certain cancers. Here, we aimed to investigate the effects of pretreatment levels of serum bilirubin and bile acids on the prognosis of patients with colorectal cancer (CRC).
METHODS: A retrospective cohort of 1474 patients with CRC who underwent surgical resection between January 2015 and December 2017 was included in the study. Survival analysis was used to evaluate the predictive value of pretreatment levels of bilirubin and bile acids. X-Tile software was used to identify optimal cut-off values for total bilirubin (TBIL), direct bilirubin (DBIL) and TBA in terms of overall survival (OS) and disease-free survival (DFS).
RESULTS: DBIL, TBIL, and TBA were validated as significant prognostic factors by univariate Cox regression analysis for both 3-year OS and DFS. Multivariate Cox regression analyses confirmed that high DBIL, TBIL and TBA levels were independent prognostic factors for both OS (HR: 0.435, 95% CI: 0.299-0.637, P < 0.001; HR: 0.436, 95% CI: 0.329-0.578, P < 0.001; HR: 0.206, 95% CI: 0.124-0.341, P < 0.001, respectively) and DFS (HR: 0.583, 95% CI: 0.391-0.871, P = 0.008; HR:0.437,95% CI: 0.292-0.655, P <0.001; HR: 0.634, 95% CI: 0.465-0.865, P = 0.004, respectively). In addition, nomograms for OS and DFS were established according to all significant factors, and the c-indexes were 0.819 (95% CI: 0.806-0.832) and 0.835 (95% CI: 0.822-0.849), respectively.
CONCLUSIONS: TBIL, DBIL and TBA levels are independent prognostic factors in colorectal cancer patients. The nomograms based on OS and DFS can be used as a practical model for evaluating the prognosis of CRC patients.

Entities:  

Keywords:  Colorectal cancer; Direct bilirubin; Survival analysis; Total bile acid; Total bilirubin

Mesh:

Substances:

Year:  2021        PMID: 33478423      PMCID: PMC7818769          DOI: 10.1186/s12885-021-07805-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  28 in total

Review 1.  Bile acids and colon cancer: Is FXR the solution of the conundrum?

Authors:  Raffaella Maria Gadaleta; Oihane Garcia-Irigoyen; Antonio Moschetta
Journal:  Mol Aspects Med       Date:  2017-04-21

2.  Quality Focus: Trends in Incidence and Mortality of Early Age Onset Colorectal Cancer in South Dakota.

Authors:  Patricia Da Rosa
Journal:  S D Med       Date:  2020-03

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  The prognostic impact of serum bilirubin in stage IV colorectal cancer patients.

Authors:  Lin Yang; Lu-Yao Ge; Ting Yu; Yan Liang; Ying Yin; Hong Chen
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

5.  Relationship between red blood cell distribution width, bilirubin, and clinical characteristics of patients with gastric cancer.

Authors:  T-T Wei; L-L Wang; J-R Yin; Y-T Liu; B-D Qin; J-Y Li; X Yin; L Zhou; R-Q Zhong
Journal:  Int J Lab Hematol       Date:  2017-05-12       Impact factor: 2.877

6.  Serum bilirubin and risk of respiratory disease and death.

Authors:  Laura J Horsfall; Greta Rait; Kate Walters; Dallas M Swallow; Stephen P Pereira; Irwin Nazareth; Irene Petersen
Journal:  JAMA       Date:  2011-02-16       Impact factor: 56.272

7.  Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator.

Authors:  Magdalena Ogłuszka; Magdalena Orzechowska; Dorota Jędroszka; Piotr Witas; Andrzej K Bednarek
Journal:  Comput Methods Programs Biomed       Date:  2019-05-23       Impact factor: 5.428

8.  Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients.

Authors:  Brianna Croft; Melissa Reed; Caitlyn Patrick; Natalie Kovacevich; Ioannis A Voutsadakis
Journal:  J Gastrointest Cancer       Date:  2019-06

9.  Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.

Authors:  Omar Abdel-Rahman
Journal:  Clin Colorectal Cancer       Date:  2018-09-27       Impact factor: 4.481

10.  Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution.

Authors:  Keizo Yamaguchi; Yutaka Ogata; Yoshito Akagi; Kazuo Shirouzu
Journal:  Oncol Lett       Date:  2013-07-01       Impact factor: 2.967

View more
  2 in total

1.  Bile acid distributions, sex-specificity, and prognosis in colorectal cancer.

Authors:  Yuping Cai; Xinyi Shen; Lingeng Lu; Hong Yan; Huang Huang; Patricia Gaule; Engjel Muca; Casey M Theriot; Zahra Rattray; Nicholas J W Rattray; Jun Lu; Nita Ahuja; Yawei Zhang; Philip B Paty; Sajid A Khan; Caroline H Johnson
Journal:  Biol Sex Differ       Date:  2022-10-23       Impact factor: 8.811

2.  An exploratory study on TCM syndrome differentiation in preoperative patients with colorectal cancer assisted by laboratory indicators.

Authors:  Ya-Nan Wang; Min Zou; Dou Wang; Zhi-Kuan Zhang; Lian-Ping Qu; Jing Xu; Cai-Dong Shi; Feng Gao
Journal:  Heliyon       Date:  2022-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.